Cancer-fighting antibodies with a one-two punch take aim at tumours

TL;DR - A Nature news feature (not a primary research paper) reporting that bispecific antibodies — engineered to bind two targets at once — are moving rapidly into clinical use for cancer, spurring development of even more complex multi-specific formats. It matters as a signal of where protein/antibody engineering pipelines are heading, an area increasingly touched by computational design.

• Bispecific antibodies bind two distinct targets simultaneously, the "one-two punch" framing used for tumour targeting.
• The piece characterizes them as "sweeping into the clinic," i.e. a shift from experimental modality to deployed cancer therapeutics.
• Clinical traction is driving work on "even more elaborate versions" (e.g. tri-/multi-specific and more complex architectures).
• Caveat: the provided content is thin — only the headline and a one-sentence abstract-style blurb — so no trial data, targets, efficacy numbers, or company/product specifics are available, and no AI/computational methods are mentioned in the source text.